Navigation Links
Oramed to Present at Oppenheimer Annual Israeli Conference
Date:5/16/2016

JERUSALEM, May 16, 2016 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Oppenheimer Annual Israeli Conference, taking place on May 22, 2016 in Tel Aviv. Nadav Kidron, CEO of Oramed, will present a corporate overview at the conference.

Presentation Details: 

Oppenheimer 17th Annual Israeli Conference 

Date: May 22, 2016 Presenter: Nadav Kidron, Chief Executive Officer Time: 1:45 pm Israel Time Location: David Intercontinental Hotel, Tel Aviv, Israel

About Oramed Pharmaceuticals 
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

For more information, the content of which is not part of this press release, please visit http://www.oramed.com

Forward-looking statements:  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials and revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.


Company Contact
Oramed Pharmaceuticals
Estee Yaari
Office: +972-2-566-0001 ext. 2
US: +1-718-831-2512 ext. 2
Email: estee@oramed.com


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Oramed Patent Being Granted in China for Oral Administration of Proteins
2. Oramed to Present at PIONEERS 2016, Presented by Joseph Gunnar
3. Oramed Receives Patent Term Adjustment Extending the Term of Its U.S. Patent
4. Oramed Completes Phase IIb Oral Insulin Study
5. Oramed Patent Granted in India for Oral Administration of Proteins
6. Oramed Pharmaceuticals Shareholder Letter
7. Oramed Announces Closing of Licensing and Investment Deal with HTIT for Oral Insulin Capsule in China
8. Oramed Signs up to $50 Million Licensing and Investment Agreements for Oral Insulin Capsule in China
9. Oramed Patent Allowed in the US for Oral Administration of Proteins
10. Oramed Completes Randomization of Over 50% of Patients in Phase IIb Oral Insulin Study
11. Oramed to Present at the Rodman & Renshaw Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2020)... (PRWEB) , ... January 09, 2020 , ... R3 Stem ... providers, including over 50 first rate presentations and procedure videos. The course is incredibly ... one's malpractice carrier. , For years, R3 Stem Cell has been the leader for ...
(Date:1/7/2020)... , ... January 07, 2020 , ... ... enterprises and telecom service providers, announced today it has been selected by MetLife ... network infrastructure. , “As part of our ongoing commitment to maintain the ...
(Date:1/7/2020)... , ... January 07, 2020 , ... ... Webinar, Tuesday, Jan. 21, 2020, 11:00 a.m.-12:30 p.m. EST, https://www.fdanews.com/chinanpma , ... globally. It is the only market with a 20 percent annual growth rate ...
Breaking Medicine Technology:
(Date:1/7/2020)... DAYTON, Ohio (PRWEB) , ... January 07, 2020 ... ... and veterinary equipment, technology and services, today identified six trends that will significantly ... still occur. , “Arguably, the time shared between a provider and patient ...
(Date:1/7/2020)... ... January 07, 2020 , ... Twenty-six people, all but one who live ... others living with YOPD attend the 6th World Parkinson Congress. The participants, representing ... back to cover all 52 weeks in 2020. The group aims to raise at ...
(Date:1/7/2020)... ANGELES (PRWEB) , ... January 06, 2020 , ... A ... a correlation between weight loss surgery and fewer complications including high blood pressure and ... had bariatric surgery between their first and their second pregnancies were less likely to ...
(Date:1/5/2020)... ... January 04, 2020 , ... NJ Top Dentist, Dr. Irvin B. Sherman has ... treatment for infants, children, teens and the special needs patient. The practice is located ... and oral health. , Dr. Sherman and his practice will be addressing issues that ...
(Date:1/3/2020)... ... 03, 2020 , ... Liz Barlowe, MA, CMC was recently ... Aging Life Care Professionals® have advanced degrees and are experts in health and ... work with the family to provide recommendations for needed goods and services to ...
Breaking Medicine News(10 mins):